Repligen (NASDAQ:RGEN) Given New $205.00 Price Target at Royal Bank of Canada

Repligen (NASDAQ:RGEN) had its target price boosted by Royal Bank of Canada from $203.00 to $205.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group boosted their price target on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday. TD Cowen initiated coverage on Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday. Finally, Wolfe Research assumed coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $183.36.

Repligen Trading Down 2.3 %

Shares of Repligen stock opened at $158.99 on Friday. The stock has a 50 day moving average of $155.22 and a 200 day moving average of $148.79. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a market capitalization of $8.91 billion, a price-to-earnings ratio of -429.69, a PEG ratio of 4.23 and a beta of 0.99. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $203.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. As a group, research analysts predict that Repligen will post 1.54 earnings per share for the current year.

Hedge Funds Weigh In On Repligen

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. GTS Securities LLC purchased a new stake in shares of Repligen during the fourth quarter worth approximately $264,000. Gordian Capital Singapore Pte Ltd purchased a new position in Repligen in the fourth quarter worth approximately $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Repligen by 12.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 235,343 shares of the biotechnology company’s stock valued at $33,875,000 after purchasing an additional 26,733 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of Repligen by 6.7% in the 4th quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company’s stock valued at $19,403,000 after purchasing an additional 8,500 shares in the last quarter. Finally, Raiffeisen Bank International AG acquired a new stake in shares of Repligen in the 4th quarter valued at $29,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.